ArticleJournal of diabetes investigation2021
Two types of fulminant type 1 diabetes mellitus: Immune checkpoint inhibitor-related and conventional.
Article in Journal of diabetes investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 11 citations in OpenAlex.
- Fulminant type 1 diabetes mellitus induced by tislelizumab in a patient with lung adenocarcinoma: a case report.Journal of medical case reports · 2026Article
- Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis.Frontiers in endocrinology · 2026Review
- [Fulminant type 1 diabetes mellitus with acute pancreatitis: A case report and literature review].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Review
- Two cases of conventional fulminant type 1 diabetes: following the depletion process of endogenous insulin secretion and literature review.Diabetology international · 2024Article
- Type 1 diabetes: immune pathology and novel therapeutic approaches.Diabetology international · 2024Review
- Immune checkpoint inhibitor-related type 1 diabetes mellitus which develops long after treatment discontinuation: a case report and review of literature.Diabetology international · 2024Article
- A case of rapidly progressive insulin-dependent diabetes mellitus without islet autoantibodies developed over two years after the first dose of nivolumab.Diabetology international · 2024Article
- A Case of Type 1 Diabetes Mellitus With Endogenous Insulin Secretory Depletion Confirmed in Two Weeks.Cureus · 2024Article
- Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes.Frontiers in endocrinology · 2024Article
- Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: A case report and review of 8 cases.Medicine · 2022Article
- Two types of fulminant type 1 diabetes mellitus: Immune checkpoint inhibitor-related and conventional.Journal of diabetes investigation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.